I'm registered for BIO Partnering @JPM Week - join me to use the BIO One-on-One Partnering system! https://lnkd.in/gqvfqDF8
关于我们
Saros Therapeutics is working to enhance patients' response to immunotherapy by harnessing the STING pathway with a strategy to overcome the limitations of prior STING agonists. In combination with existing immunotherapies, this approach has the potential to enable a safe and more effective immune response against the tumor than with immunotherapy alone.
- 网站
-
https://www.sarostx.com/
Saros Therapeutics的外部链接
- 所属行业
- 生物技术
- 规模
- 2-10 人
- 总部
- Chicago
- 类型
- 私人持股
地点
-
主要
获取路线
US，Chicago
Saros Therapeutics员工
-
Tom Denison
CEO @ SmartHealth Catalyzer, Inc. | Biomedical Venture Creation
-
Matt Martin
Biotech investor and entrepreneur bringing research to the clinic
-
Yu Leo Lei
Associate Professor of Head and Neck Surgery (tenured), of Cancer Biology, and of Translational Molecular Pathology, the University of Texas M.D…
-
Eileah Loda
Postdoctoral Research Scientist
动态
-
Richard Johnson and Matt Martin welcoming Saros' newest team member: Senior Scientist Oana Teodora Truica (Marisca). Oana is bringing a wealth of relevant nanoparticle experience and great enthusiasm to develop new therapeutics. Welcome!
-
-
I am delighted that Saros Therapeutics is participating in the Creative Destruction Lab #cancer stream. Thank you to all of the mentors for your feedback and ideas!
-
-
I really enjoyed presenting Saros Therapeutics to the local crowd at the Cooley LLP Chicago Capital Call. It was great to see a lot of friends from the Chicago #Biotech community. We had some very knowledgeable and experienced investors and operators open the event with an encouraging discussion. Thank you to Henry Gosebruch, Omar H. Khalil, Niels Emmerich, Chris Garabedian, and Andy Kadlec for sharing your thoughts with everyone. And, thanks again to Cooley LLP for organizing and hosting!
-